Drugs / Omiganan
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03071679 | Feb → Mar 2017 | — | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03688971 | Oct 2018 → Dec 2019 | seborrheic dermatitis | Maruho Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03091426 | Mar → Dec 2017 | atopic eczema | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02849262 | Jul 2016 → Mar 2017 | anogenital human papillomavirus infection | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02596074 | Nov 2015 → Mar 2017 | vulvar intraepithelial neoplasia | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02571998 | Oct 2015 → Aug 2016 | acne | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02456480 | May → Nov 2015 | atopic eczema | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 35 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT02547441 | Dec 2015 → Jul 2017 | rosacea | Maruho Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02576860 | Oct 2015 → Feb 2017 | rosacea | Maruho Co., Ltd. | Completed | Missed primary |
| Phase 3 | NCT02576847 | Oct 2015 → Jul 2017 | rosacea | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00608959 | May → Jun 2008 | infectious disease | Cadence Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00231153 | Aug 2005 → Jun 2008 | infectious disease | Cadence Pharmaceuticals | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01784133 Comparator | Mar 2013 → Mar 2014 | rosacea | Maruho Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omiganan | “Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis.” PMID 32315497 ↗ May 2020 |
| Known as | CLS001 | “Drug: Omiganan (CLS001) topical gel” NCT02596074 ↗4“Omiganan (CLS001) topical gel” NCT02849262 ↗ “Omiganan (CLS001) Topical Gel” NCT02571998 ↗ “Drug: CLS001 (Omiganan)” NCT02576860 ↗ “CLS001 (Omiganan)” NCT02547441 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1615933 ↗ |
| Route | Topical | “Patients randomized to the omiganan 1% gel group will receive an application of omiganan 1% gel around the catheter insertion site following catheter insertion.” NCT00231153 ↗ |